Ann Lab Med.  2014 May;34(3):247-251. 10.3343/alm.2014.34.3.247.

A Case of Isolated Lymphoblastic Relapse of the Central Nervous System in a Patient with Chronic Myelogenous Leukemia Treated with Imatinib

• Park MJ
• Park PW
• Seo YH
• Kim KH
• Seo JY
• Jeong JH
• Kim MJ
• Jeong JW
• Ahn JY
• Park J

• KMID: 1791929
• DOI: http://doi.org/10.3343/alm.2014.34.3.247

Abstract

No abstract available.

MeSH Terms

Antineoplastic Agents/*therapeutic use
Benzamides/*therapeutic use
Central Nervous System Neoplasms/*diagnosis
Fusion Proteins, bcr-abl/genetics
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy
Leukocytes/metabolism/pathology
Male
Middle Aged
Neoplasm Recurrence, Local
Piperazines/*therapeutic use
Pyrimidines/*therapeutic use
Antineoplastic Agents
Benzamides
Fusion Proteins, bcr-abl
Piperazines
Pyrimidines

Figure

• 

  Fig. 1 Cerebrospinal fluid (CSF) findings at seven months after initial diagnosis of CML. (A) Cytospin-smeared CSF showing numerous lymphoid cells with high nuclear-to-cytoplasmic ratio and coarse chromatin pattern with prominent nucleoli (Wright stain, ×1,000). (B) The major BCR-ABL1 fusion transcript (b2a2 type) was detected in the CSF sample using reverse transcriptase-PCR. (C) Peripheral blood smear showing slightly increased white blood cell count including neutrophils with left-shiftness. No malignant lymphoid cells are seen (Wright stain, ×1,000). (D) Bone marrow aspirate smear showing myeloid hyperplasia without definite lymphoblasts (Wright stain, ×1,000).

Reference

1. Leis JF, Stepan DE, Curtin PT, Ford JM, Peng B, Schubach S, et al. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma. 2004; 45:695–698. PMID: 15160941.

2. Rajappa S, Uppin SG, Raghunadharao D, Rao IS, Surath A. Isolated central nervous system blast crisis in chronic myeloid leukemia. Hematol Oncol. 2004; 22:179–181. PMID: 15995975.

3. Bornhauser M, Jenke A, Freiberg-Richter J, Radke J, Schuler US, Mohr B, et al. CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid. Ann Hematol. 2004; 83:401–402. PMID: 14673623.

4. Bujassoum S, Rifkind J, Lipton JH. Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy. Leuk Lymphoma. 2004; 45:401–403. PMID: 15101732.

5. Johnson NA, Fetni R, Caplan SN. Isolated central nervous system relapse in patients with chronic myeloid leukemia on imatinib mesylate. Leuk Lymphoma. 2005; 46:629–630. PMID: 16019496.

6. Matsuda M, Morita Y, Shimada T, Miyatake J, Hirase C, Tanaka M, et al. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate. Int J Hematol. 2005; 81:307–309. PMID: 15914360.

7. Aichberger KJ, Herndlhofer S, Agis H, Sperr WR, Esterbauer H, Rabitsch W, et al. Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy. Eur J Clin Invest. 2007; 37:808–813. PMID: 17727673.

8. Barlow A, Robertson M, Doig A, Stewart W, Drummond MW. Isolated central nervous system lymphoid blast crisis in chronic myeloid leukaemia in major molecular remission. Br J Haematol. 2008; 142:327. PMID: 18492112.

9. Altintas A, Cil T, Kilinc I, Kaplan MA, Ayyildiz O. Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report. J Neurooncol. 2007; 84:103–105. PMID: 17318411.

10. Isobe Y, Sugimoto K, Masuda A, Hamano Y, Oshimi K. Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate. Intern Med J. 2009; 39:408–411. PMID: 19580620.

11. Thomas A, Stein CK, Gentile TC, Shah CM. Isolated CNS relapse of CML after bone marrow transplantation. Leuk Res. 2010; 34:e113–e114. PMID: 19811825.

12. Fuchs M, Reinhöfer M, Ragoschke-Schumm A, Sayer HG, Böer K, Witte OW, et al. Isolated central nervous system relapse of chronic myeloid leukemia after allogenic hematopoietic stem cell transplantation. BMC Blood Disord. 2012; 12:9. PMID: 22871019.

13. Nishimoto M, Nakamae H, Koh KR, Kosaka S, Matsumoto K, Morita K, et al. Dasatinib maintenance therapy after allogeneic hematopoietic stem cell transplantation for an isolated central nervous system blast crisis in chronic myelogenous leukemia. Acta Haematologica. 2013; 130:111–114. PMID: 23548721.

14. Kim HJ, Jung CW, Kim K, Ahn JS, Kim WS, Park K, et al. Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib. J Clin Oncol. 2006; 24:4028–4029. PMID: 16921058.

15. Lee KW, Song MK, Seol YM, Choi YJ, Shin HJ, Chung JS, et al. Isolated central nervous system blast crisis in chronic myeloid leukemia. Korean J Med. 2009; 77(S2):S441–S444.

16. Cortes J, Goldman JM, Hughes T. Current issues in chronic myeloid leukemia: monitoring, resistance, and functional care. J Natl Compr Canc Netw. 2012; 10(S3):S1–S13. PMID: 23055247.

17. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27:6041–6051. PMID: 19884523.

18. Forrest DL, Trainor S, Brinkman RR, Barnett MJ, Hogge DE, Nevill TJ, et al. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res. 2009; 33:271–275. PMID: 18762338.

19. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998; 90:850–859. PMID: 9625174.

20. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984; 63:789–799. PMID: 6584184.